CoChat

Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization

Open access
Soden, Peter A., Zettervall, Sara L., Ultee, Klaas H.J., Landon, Bruce E., O'Malley, A. James, Goodney, Philip P., DeMartino, Randall R., Arya, Shipra, Schermerhorn, Marc L. · 2016 · Journal of Vascular Surgery
Cited by 59

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Introduction Dual antiplatelet therapy (DAPT) after coronary stenting prolongs survival by preventing both in-stent thrombosis and other cardiovascular atherothrombotic events. Patients with peripheral artery disease (PAD) typically have a heavy burden of unrevascularized coronary artery disease and also stand to benefit from increased atherothrombotic protection with DAPT. The potential benefit of DAPT compared to aspirin alone in patients with PAD is not well described. Methods We identified all patients undergoing an initial elective lower extremity revascularization (bypass or endovascular) from 2003 to 2016 in the Vascular Quality Initiative (VQI) registry discharged on aspirin or aspirin plus a thenopyradine anti-platelet agent (dual anti-platelet therapy (DAPT)). We first estimated models predicting the likelihood of receiving DAPT and then used inverse probability weighting to account for baseline differences in the likelihood to receive DAPT and compared late survival. For sensitivity analysis we also performed Cox proportion hazard modeling on the unweighted cohorts and generated adjusted survival curves. Results We identified 57,041 patients undergoing lower extremity revascularization (28% bypass). Of 15,985 bypasses (69% for critical limb ischemia (CLI)) 38% were discharged on DAPT. Of 41,056 endovascular interventions (39% for CLI) 69% were discharged on DAPT. Analyses using inverse probability weighting demonstrated small survival benefits to DAPT at one-year for bypass (93% vs. 92%, P = .001) and endovascular interventions (93% vs. 92%, P = .005) that was sustained through five-years of follow-up (bypass: 80% vs. 78%, P = .004; Endovascular: 76% vs. 73%, P = .002). When stratified by severity of PAD, DAPT had a survival benefit for patients with CLI undergoing bypass (five-year: 70% vs. 66%, P = .04) and endovascular intervention (five-year: 71% vs. 67%, P = .01) but not for patients with claudication (bypass: 89% vs. 88%, P = .36; endovascular: 87% vs. 85%, P = .46). The protective effect of DAPT was similar when using Cox Proportional hazard models after bypass (HR 0.81, 95% CI 0.72 – 0.90) and endovascular intervention (HR 0.89, 0.83 – 0.95). Conclusion Dual antiplatelet therapy at time of discharge was associated with prolonged survival for patients with CLI undergoing lower extremity revascularization but not for those with claudication. Further research is needed to quantify the risks associated with DAPT and to identify subgroups at increased risk of thrombotic and bleeding complications in order to guide medical management of patients with PAD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jvs.2016.05.098

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Metadata

Authors
Soden, P. A., Zettervall, S. L., Ultee, K. H. J., Landon, B. E., O'Malley, A. J., Goodney, P. P., DeMartino, R. R., Arya, S., & Schermerhorn, M. L.
Venue
Journal of Vascular Surgery
Publisher
Elsevier BV
Published
2016-12
Volume
64
Issue
6
Pages
1633-1644.e1
ISSN
0741-5214 (ISSN-L)
OpenAlex
W2510098524
Cited by
59
References
12
FWCI
5.64
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.